Evaluating SEQUOIA (Arm C): Updates From ASCO 2025

Video content above is prompted by the following:

The SEQUOIA study represents a landmark advancement in treating patients with high-risk chronic lymphocytic leukemia (CLL), specifically those with TP53 mutations or 17p deletions who historically have had limited effective treatment options. This trial’s innovative design focused on evaluating zanubrutinib monotherapy in this challenging patient population, addressing a significant unmet medical need in CLL treatment. The study demonstrated that high-risk CLL patients achieved excellent progression-free survival rates with zanubrutinib, maintaining these responses at 2 and 3-year follow-up periods.

The sustained efficacy of zanubrutinib in high-risk CLL patients represents a paradigm shift for this traditionally difficult-to-treat population. Unlike previous treatments where initial responses were often followed by rapid disease progression within 12 months, zanubrutinib maintained significant anticancer activity over extended treatment periods. This durability of response is particularly noteworthy given that TP53-mutated and 17p-deleted CLL patients typically experience shorter remissions and poorer outcomes with conventional therapies.

These SEQUOIA results have transformative implications for high-risk CLL management, providing evidence-based treatment options for patients previously considered to have subpar therapeutic choices. The demonstration of maintained efficacy in this challenging patient subset establishes zanubrutinib as a game-changing therapy for high-risk CLL. This advancement addresses a critical gap in CLL treatment, offering hope for improved long-term outcomes in patients with the most aggressive forms of the disease.